Tenaya Therapeutics is trading at $0.34, down 5.11%, on November 5, 2026, amid a broad risk-off session. - The Nasdaq Composite fell 3.23% and the S&P 500 fell 1.86% as investors reassessed technology-sector and macro risks. - November 4 results were better than estimates, with a $0.08 per-share loss and $1.7 million in revenue; management projected cash runway into Q4 2027. - A Piper Sandler price-target cut was reported this morning, but the available report does not establish that it caused the decline.